Pharma Penny Stock Below Rs 15: JFL Life Sciences Receives Orders of Rs 42,59,49,700 from J D Healthcare

JFL Life Sciences Ltd. has recevied significant new business, totalling Rs 42,59,49,700 from J D Healthcare, a domestic entity. This total is split between two separate orders. The first order, valued at Rs 12,59,50,000, is for the supply of various Pharmaceutical, Lifecare, and Healthcare products. This contract mandates execution within nine months from the purchase order dated May 10, 2025. These disclosures were made by JFL Life Sciences in compliance with the Listing Regulations, 2015, highlighting the materiality of these events to the company's operations.

Also Read DSIJ Blog: Comparing India’s Defence Stocks: HAL vs BEL vs BDL – Who Could Perform Better?

The second, larger order contributes Rs 29,99,99,700 (inclusive of Taxes) to the overall total and involves the supply of a specific piece of equipment: the Merilyzer Quantilyte Machine. This contract falls under the nature of supplying a Pharmaceutical/Healthcare Instrument and has a shorter execution timeline of 180 days. Combined, these two contracts demonstrate a substantial commitment from J D Healthcare to source both a diverse range of products and specialised medical equipment from JFL Life Sciences.

JFL Life Sciences Limited, a WHO-GMP-certified Indian pharmaceutical company established in 2010, manufactures a diverse range of products, including dry powder injections, tablets, capsules, and oral rehydration solutions. With a focus on β-lactam formulations, the company offers over 320 products across various dosage forms. The company has a market cap of Rs 55 crore.

The promoters of the company hold 67.47 per cent and the public owns a 32.53 per cent stake in the company as of September 2025. The shares of the company have a PE of 13x whereas the industry PE is 35x. The stock is up over 10 per cent from its 52-week low of Rs 11.85 per share.

Disclaimer: The article is for informational purposes only and not investment advice.